Leerink Partners Maintains Outperform on Progyny, Raises Price Target to $38
Leerink Partners analyst Michael Cherny maintains Progyny (NASDAQ:PGNY) with a Outperform and raises the price target from $37 to $38.
Share
Why It Matters
An analyst who follows Progyny thinks the company is doing well. They raised their expected price target by one dollar to thirty eight dollars.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.